Search

Alzheimer disease (AD) is a widespread neurodegenerative disease characterized by the accumulation of oligomeric toxic forms of β-amyloid (Aβ1-42) and dysfunction of the cholinergic system in the different brain regions. However, the exact mechanisms of AD pathogenesis and the role of the nicotinic acetylcholine receptors (nAChRs) in the disease progression remain unclear. Here, we revealed a decreased expression of a number of the Ly6/uPAR proteins targeting nAChRs in the cerebellum of 2xTg-AD mice (model of early AD) in comparison with non-transgenic mice both at mRNA and protein levels. We showed that co-localization of one of them, – neuromodulator Lynx1, with α7-nAChR was diminished in the vicinity of cerebellar astrocytes of 2xTg-AD mice, while Aβ1-42 co-localization with this receptor present was increased. Moreover, the expression of anti-inflammatory transcription factor KLF4 regulating transcription of the Ly6/uPAR genes was decreased in the cerebellum of 2xTg-AD mice, while expression of inflammatory cytokine TNF-α was increased. Based on these data together with observed astrocyte degeneration in the cerebellum of 2xTg-AD mice, we suggest the mechanism by which expression of the Ly6/uPAR proteins upon Aβ pathology results in dysregulation of the cholinergic system and particularly of α7-nAChR function in the cerebellum. This leads to enhanced neuroinflammation and cerebellar astrocyte degeneration. [ABSTRACT FROM AUTHOR]

Lynx1 is a GPI‐tethered protein colocalized with nicotinic acetylcholine receptors (nAChRs) in the brain areas important for learning and memory. Previously, we demonstrated that at low micromolar concentrations the water‐soluble Lynx1 variant lacking GPI‐anchor (ws‐Lynx1) acts on α7‐nAChRs as a positive allosteric modulator. We hypothesized that ws‐Lynx1 could be used for improvement of cognitive processes dependent on nAChRs. Here we showed that 2 µM ws‐Lynx1 increased the acetylcholine‐evoked current at α7‐nAChRs in the rat primary visual cortex L1 interneurons. At higher concentrations ws‐Lynx1 inhibits α7‐nAChRs expressed in Xenopus laevis oocytes with IC50 ~ 50 µM. In mice, ws‐Lynx1 penetrated the blood‐brain barrier upon intranasal administration and accumulated in the cortex, hippocampus, and cerebellum. Chronic ws‐Lynx1 treatment prevented the olfactory memory and motor learning impairment induced by the α7‐nAChRs inhibitor methyllycaconitine (MLA). Enhanced long‐term potentiation and increased paired‐pulse facilitation ratio were observed in the hippocampal slices incubated with ws‐Lynx1 and in the slices from ws‐Lynx1‐treated mice. Long‐term potentiation blockade observed in MLA‐treated mice was abolished by ws‐Lynx1 co‐administration. To understand the mechanism of ws‐Lynx1 action, we studied the interaction of ws‐Lynx1 and MLA at α7‐nAChRs, measured the basal concentrations of endogenous Lynx1 and the α7 nAChR subunit and their association in the mouse brain. Our findings suggest that endogenous Lynx1 limits α7‐nAChRs activation in the adult brain. Ws‐Lynx1 partially displaces Lynx1 causing positive modulation of α7‐nAChRs and enhancement of synaptic plasticity. Ws‐Lynx1 and similar compounds may constitute useful hits for treatment of cognitive deficits associated with the cholinergic system dysfunction. [ABSTRACT FROM AUTHOR]